Moderna's experimental COVID-19 vaccine induced immune responses in older adults that were similar to younger participants.
Results from the early small-scale clinical trial –released Wednesday - keeps Moderna in the race as one of the leading U.S. contenders to develop a vaccine against the novel coronavirus.
The analysis looked at a 100 microgram dosage and found the immune responses in those aged between 56 and 70 years, above 70 and those in the age-group of 18 and 55 were similar.
Moderna is already moving on to a larger late-stage clinical trial, where it has signed up more than 13,000 people to take part.
The pressure is on Moderna to come up with a winner. Even though it doesn't have any drugs on the market, the U.S. government gave Moderna nearly $1 billion towards a vaccine development. It also struck a $1.5 billion supply agreement with the company.
Investors have responded by betting big on the stock - shares have tripled in value so far this year. The stock moved higher still on Wednesday - up by as much as 7 percent in early trading.